{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265702","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.252513+00:00","generated_at":"2026-05-17T00:13:16.338478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study","bullets":["Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.","100% of participants (n=10) achieved skin FXN levels similar to asymptomatic carriers after 6 months of daily nomlabofusp in open-label study.","Anaphylaxis occurred in 7 of 65 total participants; new modified starting dose regimen implemented to mitigate risk, agreed with FDA.","BLA submission seeking accelerated approval targeted for Q2 2026, with $175.4M cash runway into Q4 2026.","Consistent directional improvement across mFARS, FARS-ADL, 9-HPT, and MFIS after 1 year versus worsening in FACOMS reference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265702","json":"https://secwatch.observer/filing/0001193125-25-265702.json","markdown":"https://secwatch.observer/filing/0001193125-25-265702.md","text":"https://secwatch.observer/filing/0001193125-25-265702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/0001193125-25-265702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T00:13:16.338478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}